These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

275 related articles for article (PubMed ID: 24627331)

  • 1. Vorapaxar, a platelet thrombin-receptor antagonist, in medically managed patients with non-ST-segment elevation acute coronary syndrome: results from the TRACER trial.
    Held C; Tricoci P; Huang Z; Van de Werf F; White HD; Armstrong PW; Ambrosio G; Aylward PE; Moliterno DJ; Wallentin L; Chen E; Erkan A; Jiang L; Strony J; Harrington RA; Mahaffey KW
    Eur Heart J Acute Cardiovasc Care; 2014 Sep; 3(3):246-56. PubMed ID: 24627331
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Vorapaxar in acute coronary syndrome patients undergoing coronary artery bypass graft surgery: subgroup analysis from the TRACER trial (Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome).
    Whellan DJ; Tricoci P; Chen E; Huang Z; Leibowitz D; Vranckx P; Marhefka GD; Held C; Nicolau JC; Storey RF; Ruzyllo W; Huber K; Sinnaeve P; Weiss AT; Dery JP; Moliterno DJ; Van de Werf F; Aylward PE; White HD; Armstrong PW; Wallentin L; Strony J; Harrington RA; Mahaffey KW
    J Am Coll Cardiol; 2014 Mar; 63(11):1048-57. PubMed ID: 24211500
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Glycoprotein IIb/IIIa Receptor Inhibitors in Combination With Vorapaxar, a Platelet Thrombin Receptor Antagonist, Among Patients With Non-ST-Segment Elevation Acute Coronary Syndromes (from the TRACER Trial).
    Cornel JH; Tricoci P; Lokhnygina Y; Moliterno DJ; Wallentin L; Armstrong PW; Aylward PE; Clare RM; Chen E; Leonardi S; Van de Werf F; White HD; Held C; Strony J; Mahaffey KW; Harrington RA
    Am J Cardiol; 2015 May; 115(10):1325-32. PubMed ID: 25776457
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effect of age on efficacy and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome: Insights from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) trial.
    Armaganijan LV; Alexander KP; Huang Z; Tricoci P; Held C; Van de Werf F; Armstrong PW; Aylward PE; White HD; Moliterno DJ; Wallentin L; Chen E; Harrington RA; Strony J; Mahaffey KW; Lopes RD
    Am Heart J; 2016 Aug; 178():176-84. PubMed ID: 27502866
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes.
    Tricoci P; Huang Z; Held C; Moliterno DJ; Armstrong PW; Van de Werf F; White HD; Aylward PE; Wallentin L; Chen E; Lokhnygina Y; Pei J; Leonardi S; Rorick TL; Kilian AM; Jennings LH; Ambrosio G; Bode C; Cequier A; Cornel JH; Diaz R; Erkan A; Huber K; Hudson MP; Jiang L; Jukema JW; Lewis BS; Lincoff AM; Montalescot G; Nicolau JC; Ogawa H; Pfisterer M; Prieto JC; Ruzyllo W; Sinnaeve PR; Storey RF; Valgimigli M; Whellan DJ; Widimsky P; Strony J; Harrington RA; Mahaffey KW;
    N Engl J Med; 2012 Jan; 366(1):20-33. PubMed ID: 22077816
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Vorapaxar with or without clopidogrel after non-ST-segment elevation acute coronary syndromes: results from the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome trial.
    Tricoci P; Lokhnygina Y; Huang Z; Van de Werf F; Cornel JH; Chen E; Wallentin L; Held C; Aylward PE; Moliterno DJ; Jennings LK; White HD; Armstrong PW; Harrington RA; Strony J; Mahaffey KW
    Am Heart J; 2014 Dec; 168(6):869-77.e1. PubMed ID: 25458650
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Use of thienopyridine prior to presentation with non-ST-segment elevation acute coronary syndrome and association with safety and efficacy of vorapaxar: insights from the TRACER trial.
    Harskamp RE; Clare RM; Ambrosio G; Held C; Lokhnygina Y; Moliterno DJ; White HD; Aylward PE; Armstrong PW; Mahaffey KW; Harrington RA; Van de Werf F; Wallentin L; Strony J; Tricoci P
    Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):155-163. PubMed ID: 26895973
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Usefulness and safety of vorapaxar in patients with non-ST-segment elevation acute coronary syndrome undergoing percutaneous coronary intervention (from the TRACER Trial).
    Valgimigli M; Tricoci P; Huang Z; Aylward PE; Armstrong PW; Van de Werf F; Leonardi S; White HD; Widimsky P; Harrington RA; Cequier A; Chen E; Lokhnygina Y; Wallentin L; Strony J; Mahaffey KW; Moliterno DJ
    Am J Cardiol; 2014 Sep; 114(5):665-73. PubMed ID: 25129064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Effect of vorapaxar on myocardial infarction in the thrombin receptor antagonist for clinical event reduction in acute coronary syndrome (TRA·CER) trial.
    Leonardi S; Tricoci P; White HD; Armstrong PW; Huang Z; Wallentin L; Aylward PE; Moliterno DJ; Van de Werf F; Chen E; Providencia L; Nordrehaug JE; Held C; Strony J; Rorick TL; Harrington RA; Mahaffey KW
    Eur Heart J; 2013 Jun; 34(23):1723-31. PubMed ID: 23530022
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Outcomes in Stable Patients With Previous Atherothrombotic Events Receiving Vorapaxar Who Experience a New Acute Coronary Event (from TRA2°P-TIMI 50).
    Berg DD; Bonaca MP; Braunwald E; Corbalan R; Goto S; Kiss RG; Murphy SA; Scirica BM; Spinar J; Morrow DA
    Am J Cardiol; 2016 Apr; 117(7):1055-8. PubMed ID: 26876014
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Reduction in overall occurrences of ischemic events with vorapaxar: results from TRACER.
    White HD; Huang Z; Tricoci P; Van de Werf F; Wallentin L; Lokhnygina Y; Moliterno DJ; Aylward PE; Mahaffey KW; Armstrong PW
    J Am Heart Assoc; 2014 Jul; 3(4):. PubMed ID: 25012288
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Association of aspirin dose and vorapaxar safety and efficacy in patients with non-ST-segment elevation acute coronary syndrome (from the TRACER Trial).
    Mahaffey KW; Huang Z; Wallentin L; Storey RF; Jennings LK; Tricoci P; White HD; Armstrong PW; Aylward PE; Moliterno DJ; Van de Werf F; Chen E; Leonardi S; Rorick T; Held C; Strony J; Harrington RA
    Am J Cardiol; 2014 Mar; 113(6):936-44. PubMed ID: 24444781
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Arterial access site and outcomes in patients undergoing percutaneous coronary intervention with and without vorapaxar.
    Déry JP; Mahaffey KW; Tricoci P; White HD; Podder M; Westerhout CM; Moliterno DJ; Harrington RA; Chen E; Strony J; Van de Werf F; Ziada KM; Held C; Aylward PE; Armstrong PW; Rao SV
    Catheter Cardiovasc Interv; 2016 Aug; 88(2):163-73. PubMed ID: 26698636
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of vorapaxar as approved for clinical use in the United States.
    Magnani G; Bonaca MP; Braunwald E; Dalby AJ; Fox KA; Murphy SA; Nicolau JC; Oude Ophuis T; Scirica BM; Spinar J; Theroux P; Morrow DA
    J Am Heart Assoc; 2015 Mar; 4(3):e001505. PubMed ID: 25792124
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vorapaxar in the secondary prevention of atherothrombotic events.
    Morrow DA; Braunwald E; Bonaca MP; Ameriso SF; Dalby AJ; Fish MP; Fox KA; Lipka LJ; Liu X; Nicolau JC; Ophuis AJ; Paolasso E; Scirica BM; Spinar J; Theroux P; Wiviott SD; Strony J; Murphy SA;
    N Engl J Med; 2012 Apr; 366(15):1404-13. PubMed ID: 22443427
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Vorapaxar for secondary prevention of thrombotic events for patients with previous myocardial infarction: a prespecified subgroup analysis of the TRA 2°P-TIMI 50 trial.
    Scirica BM; Bonaca MP; Braunwald E; De Ferrari GM; Isaza D; Lewis BS; Mehrhof F; Merlini PA; Murphy SA; Sabatine MS; Tendera M; Van de Werf F; Wilcox R; Morrow DA;
    Lancet; 2012 Oct; 380(9850):1317-24. PubMed ID: 22932716
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Atherothrombotic Risk Stratification and the Efficacy and Safety of Vorapaxar in Patients With Stable Ischemic Heart Disease and Previous Myocardial Infarction.
    Bohula EA; Bonaca MP; Braunwald E; Aylward PE; Corbalan R; De Ferrari GM; He P; Lewis BS; Merlini PA; Murphy SA; Sabatine MS; Scirica BM; Morrow DA
    Circulation; 2016 Jul; 134(4):304-13. PubMed ID: 27440003
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Vorapaxar in patients with coronary artery bypass grafting: Findings from the TRA 2°P-TIMI 50 trial.
    Kosova EC; Bonaca MP; Dellborg M; He P; Morais J; Oude Ophuis T; Scirica BM; Tendera M; Theroux P; Braunwald E; Morrow DA
    Eur Heart J Acute Cardiovasc Care; 2017 Mar; 6(2):164-172. PubMed ID: 27075924
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Vorapaxar in patients with peripheral artery disease: results from TRA2{degrees}P-TIMI 50.
    Bonaca MP; Scirica BM; Creager MA; Olin J; Bounameaux H; Dellborg M; Lamp JM; Murphy SA; Braunwald E; Morrow DA
    Circulation; 2013 Apr; 127(14):1522-9, 1529e1-6. PubMed ID: 23501976
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy and Safety of Vorapaxar in Non-ST-Segment Elevation Acute Coronary Syndrome Patients Undergoing Noncardiac Surgery.
    van Diepen S; Tricoci P; Podder M; Westerhout CM; Aylward PE; Held C; Van de Werf F; Strony J; Wallentin L; Moliterno DJ; White HD; Mahaffey KW; Harrington RA; Armstrong PW
    J Am Heart Assoc; 2015 Dec; 4(12):. PubMed ID: 26672080
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.